The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.

Matteo BaucknehtFrancesco BertagnaMaria Isabella DoneganiRexhep DurmoAlberto MiceliVincenzo De BiasiRiccardo LaudicellaGiuseppe FornariniAlfredo BerrutiSergio BaldariAnnibale VersariRaffaele GiubbiniGianmario SambucetiSilvia MorbelliDomenico Albano

Published in: Prostate cancer and prostatic diseases (2021)

FDG-PET/CT's prognostic value extends to predicting treatment response duration in mCRPC, thus potentially guiding the systemic treatment selection.

Keyphrases

end stage renal disease
ejection fraction
squamous cell carcinoma
small cell lung cancer
peritoneal dialysis
patient reported outcomes
patient reported
smoking cessation